Is there any effect of COVID-19 mRNA vaccination on electrocardiographic parameters in patients without apparent cardiovascular disease?

Abstract

Objective: Electrocardiographic alterations were investigated following the second dosage of COVID-19 mRNA vaccination. Methods: A total of 260 individuals after two doses of COVID-19 vaccine with Pfizer-BioNTech were included in the study. The electrocardiographic parameters recorded at baseline and approximately one week later after two doses of Pfizer-BioNTech vaccine were compared for all patients. Results: PR interval was increased and QTc maximum interval was decreased significantly after second dose COVID-19 mRNA vaccination. Baseline and post-second dose vaccination states regarding P wave dispersion and QT dispersion/Tp-e interval which have been recognized to imply inhomogeneous atrial conduction and heterogeneity in ventricular repolarization were similar between groups. Conclusion: Our findings suggest that there should be no concern related to asymptomatic involvement of the myocardium subsequent the second dose of COVID-19 mRNA vaccination.

Keywords

• COVID-19
• mRNA vaccine
• myocarditis
• electrocardiography
• P wave dispersion
• QT dispersion

Belirgin kardiyovasküler hastalığı olmayan hastalarda COVID-19 mRNA aşısının elektrokar-diyografik parametreler üzerinde herhangi bir etkisi var mı?

Abstract

Amaç: Bu çalışmanın amacı, ikinci doz COVID-19 mRNA aşılamasından sonra elektrokardiyografik değişi-klikleri değerlendirmektir. Yöntem: Çalışmaya Pfizer-BioNTech ile iki doz COVID-19 aşısı yapılan toplam 260 hasta dahil edildi. Başlangıçta ve iki doz Pfizer-BioNTech aşısından yaklaşık 1 hafta sonra kaydedilen elektrokardiyo-grafik parametreler tüm hastalar için karşılaştırıldı. Bulgular: İkinci doz COVID-19 mRNA aşılamasından sonra PR aralığı arttı ve QTc maksimum aralığı önemli ölçüde azaldı. Sırasıyla ventriküler repolarizasyonda homojen olmayan atriyal iletimi ve heterojenliği yansıttığı varsayılan P dalgası dispersiyonu ve QT dispersiyonu/Tp-e aralığı ile ilgili olarak başlangıç ve ikinci doz aşılama durumları arasında anlamlı bir fark yoktu. Sonuç: Bulgularımız, ikinci doz COVID-19 mRNA aşılamasından sonra miyokardın asemptomatik tutulumu ile ilgili herhangi bir endişe olmaması gerektiğini düşündürmektedir.

Keywords

• COVID-19
• mRNA aşısı
• miyokardit
• elektrokardiyografi
• P dalga dispersiyonu
• QT dispersiyonu

References

1. 1. Soumya RS, Unni TG, Raghu KG. Impact of COVID-19 on the cardiovascular system: A review of available reports. Cardiovasc Drugs Ther 2021;35(3):411-25. doi: 10.1007/s10 557-020-07073-y.
2. 2. Woo W, Kim AY, Yon DK, et al. Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine. J Med Virol 2022;94(4):1566-80. doi: 10.1002/jmv.27501.
3. 3. Hause AM, Gee J, Baggs J, et al. COVID-19 vaccine safety in adolescents aged 12-17 years-United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep 2021;70(31):1053-8. doi: 10.15585/mmwr.mm7031e1.
4. 4. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nation-wide setting. N Engl J Med 2021;385(12):1078-90. doi: 10.1056/NEJ Moa2110475.
5. 5. Jeet Kaur R, Dutta S, Charan J, et al. Cardiovascular adverse events reported from COVID-19 vaccines: A study based on WHO database. Int J Gen Med 2021;14:3909-27. doi: 10.2147/IJGM.S324349.
6. 6. Matta A, Kallamadi R, Matta D, Bande D. Post-mRNA COVID-19 vaccination myocarditis. Eur J Case Rep Intern Med 2021;8(8):002769. doi: 10.12890/2021_002769.
7. 7. Fatima M, Ahmad Cheema H, Ahmed Khan MH, et al. Development of myocarditis and pericarditis after COVID-19 vaccination in adult population: A systematic review. Ann Med Surg (Lond) 2022;76:103486. doi: 10.1016/j.amsu.2022 .103486.
8. 8. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol 2012;59(9):779-92. doi: 10.1016 /j.jacc.2011.09.074.

9. 9. Castro-Torres Y, Carmona-Puerta R, Katholi RE. Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice. World J Clin Cases 2015;3(8):705-20. doi: 10.12998/wjcc.v3.i8.705.
10. 10. Tsilingiris D, Vallianou NG, Karampela I, Liu J, Dalamaga M. Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2. Metabol Open 2022;13:100159. doi: 10.1016/j.metop.2021.100159.
11. 11. Fung G, Luo H, Qiu Y, Yang D, McManus B. Myocarditis. Circ Res 2016;118(3):496-514. doi: 10.1161/CIRCRES AHA.115.306573.